Bladder Cancer: Molecular Basis and Translational Research
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 3135
Special Issue Editors
Interests: uro-oncology; bladder cancer; cancer cell biology; bladder cancer cell cultures; bladder cancer organoids; biomarkers; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: uro-oncology; bladder cancer; upper-tract urothelial carcinoma; endourology
Special Issues, Collections and Topics in MDPI journals
Interests: uro-oncology; lymph node metastasis-growth and immune evasion; minimally invasive surgery; radio-guided surgery; prostate cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a new Special Issue for Biomedicines entitled "Bladder Cancer: From Pathophysiology to Novel Therapeutic Approaches".
Bladder cancer is one of the most common malignancies of the urinary system, with approximately 500,000 individuals diagnosed annually worldwide. It is a heterogeneous disease associated with various clinical outcomes. The majority of non-muscle-invasive bladder cancers (NMIBCs) can be managed with total curative intent, while the treatment of muscle-invasive bladder cancer (MIBC) is challenging and often multimodal. Despite the standard treatment (radical cystectomy with pelvic lymph node dissection), almost 50% of patients with MIBC will eventually develop metastatic disease, which is associated with poor survival rates. The systemic management of advanced or metastatic MIBC primarily consists of platinum-based chemotherapy; however, it provides an approximately 50% response rate with only a 20% five-year overall survival rate. One of the most important discoveries in recent years, facilitating the treatment of advanced or metastatic MIBC, has been the introduction of drugs targeting immune checkpoints: programmed death receptor 1 (PD-1) and programmed death receptor 1 ligand (PD-L1) inhibitors. Nevertheless, despite their efficacy, only a small proportion of patients clearly benefit from such treatment, which is mainly dependent on PD-1/PD-L1 expression levels. Due to the above-mentioned limitations of current bladder cancer therapies, there is an urgent need to promote studies that aim to understand the molecular mechanisms underlying bladder cancer carcinogenesis, progression, and metastasis, as well as develop novel strategies for treating and improving the cancer-specific and overall survival of patients with bladder cancer.
In this Special Issue, we will cover the following research topics:
- Novel translational models of bladder cancer (3D cellular cultures, organoids) that enable research into bladder cancer carcinogenesis, progression, metastasis, and novel molecularly-targeted therapeutic approaches;
- The discovery of novel and reliable bladder cancer biomarkers (diagnostic and prognostic);
- Updates on pharmacological therapeutic approaches, clinical trials, and FDA-approved drugs for the treatment of bladder cancer.
This Special Issue welcomes original research articles, as well as comprehensive reviews, that will provide valuable new data.
Dr. Łukasz Nowak
Dr. Wojciech Krajewski
Dr. Bartosz Małkiewicz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- preclinical models of bladder cancer
- molecular characterization
- biomarkers
- radical cystectomy
- chemotherapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.